TRIAL OF PACLITAXEL AND CARBOPLATIN VERSUS COMBINATIONS IN PATIENTS WITH CANCER

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。在美国，卵巢癌和原发性腹膜癌每年侵袭超过20，000名妇女。大多数女性都患有晚期疾病。那些患有晚期疾病的人会有更高的复发率或持续性疾病。手术后的标准药物治疗是两种铂类药物（卡铂，紫杉醇，最近顺铂）。尽管最近在管理方面有所改善，但仍有相当数量的患者（约25%）会出现癌症复发。因此，挑战在于找到将改善总体存活率并降低复发百分比的最佳治疗方案药剂。有三种新药已被证明在治疗卵巢癌和腹膜癌方面取得了成功。这些药物是吉西他滨、托泊替康和Doxil单独给药或与标准治疗联合给药。 本研究将观察在卡铂或紫杉醇的标准药物方案中添加这些药物之一的有效性。 研究表明，卵巢癌可以在家庭中运行。BRCA 1和BRCA 2是在这些女性的血液或肿瘤中发现的两种基因。这些女性对化疗的反应可能与没有这些基因的女性不同。因此，这项研究的第二个目的是看看有这些基因的女性的生存率是否有差异。将分析血液和肿瘤组织，以确定研究中具有这些基因的患者，并将其与不具有这些基因的女性进行比较。 这项研究还将研究与标准治疗相比与新组合相关的副作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Ovarian cancer and primary peritoneal cancer strikes over 20,000 women each year in the United States. Most women present with advanced disease. Those with advanced disease will have higher rates of relapse or persistent disease. The standard drug treatment following surgery is with two platinum-based drugs (Carboplatin, paclitaxel, and more recently cisplatin). Despite recent improvement in management, a significant number of patients, approximately 25% will have a recurrence of their cancer. Thus, the challenge is to find an optimal treatment regimen agent(s) that will improve overall survival, and decrease the percentage of recurrence. There are three new drugs which have been shown to be successful in the treatment of ovarian and peritoneal cancer. These drugs are Gemcitabene, Topotecan and Doxil given alone or in combination with the standard treatments. This study will look at the effectiveness of adding one of these drugs to the standard drug regimen of Carboplatin or Paclitaxel. Studies have shown that ovarian cancer can run in families. BRCA 1 and BRCA 2 are two genes that have been found in the blood or tumors of these women. It is possible that these women may respond differently to chemotherapy treatment than women who do not have one of these genes. Therefore, a second purpose of this study is to look at whether there is a difference in survival in women who have these genes. Blood and tumor tissue will be analyzed in order to identify these patients in the study who have these genes and compare them to women who do not. This study will also look at the side effects associated with the new combinations compared to the standard treatments.